Also Read
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Adults who are overweight, obese or have type 2 diabetes might be able to benefit from Danish-made Victoza, which, in its third phase of clinical trials, proved successful in weight management. Its chemical name is liraglutide and when given in 3mg doses over a 56-week period, combined with proper diet and exercise, trial participants experienced a 5.9 percent mean loss of baseline body weight.
Smaller doses of the drug led to a slightly reduced mean weight loss of 4.6 percent and the control group's mean weight loss was just two percent. All three groups followed a low calorie diet and exercise regimen for the duration of the study. According to Dr. Maria Collazo-Clavel, an associate professor at College of Medicine, Mayo Clinic and medical editor of diabetes content on Mayo's health information website and for 'Mayo Clinic The Essential Diabetes Book,' the drug works mainly by suppressing appetite. (Read: Go vegan to prevent and reverse diabetes (World Diabetes Day 2013))
She says on the Mayo Clinic's website that the drug delays the passage of food from the stomach to the small intestine, increasing the amount of time in which the patient is satiated. If approved for use as a weight loss medication, the drug could serve an important patient group. 'Weight loss and weight management are generally much harder for people who are overweight or obese and who also have type 2 diabetes,' said Dr. Robert Kushner, Clinical Director, Northwestern Comprehensive Center on Obesity, Chicago. 'Given the challenges faced by this patient population, the 5.9% weight loss seen with liraglutide 3 mg in this study is impressive. (Read: 10 ways to control diabetes naturally)
Another positive result of the study was the reduction in blood glucose of 1.3 percent in the group that received liraglutide in the 3mg doses. Some side effects, mostly gastro-intestinal complications such as nausea, were reported. Danish pharmaceutical company Novo Nordisk is currently awaiting response from the Food and Drug Administration (FDA) and European Medicines Association (EMA) for approval as a weight management drug for overweight and obese adults. Liraglutide is currently sold in the United States in smaller, injectable doses to control type 2 diabetes. 'There is a real need for effective treatment options for adults with obesity and type 2 diabetes that can demonstrate clinically meaningful weight loss and improve serious weight-related comorbidities,' says Dr. Kushner. (Read: Expert diet and exercise tips to manage diabetes)
You may also like to read:
For more on diabetes, check out our diabetes section. Follow us on Facebook and Twitter for all the latest updates! For daily free health tips, sign up for our newsletter. And to join discussions on health topics of your choice, visit our forum.